FDA grants priority review to Genentech’s Tecentriq as first-line treatment of certain people with advanced NSCLC
The FDA is expected to make a decision on approval by June 19, 2020. “In the IMpower110 study, Tecentriq alone demonstrated a significant improvement in overall survival compared